| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer. |
| 掲載誌名 | 正式名：Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 略 称：Pancreatology ISSNコード：14243911/14243903 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 25(4),pp.544-551 |
| 著者・共著者 | Haruyoshi Tanaka, Kenichi Hirabayashi, Tsutomu Fujii, Nobuyuki Ohike, Makoto Ueno, Takahiro Mizui, Masaharu Ishida, Shinichi Egawa, Toru Furukawa, Yuichi Nagakawa, Takao Itoi, Hirohisa Kitagawa, Yohei Masugi, Masaji Tani, Noriyoshi Fukushima, Takashi Hatori, Yosuke Tajika, Sohei Satoi, Michiaki Unno, Yoshifumi Takeyama |
| 発行年月 | 2025/06 |
| 概要 | BACKGROUND/OBJECTIVES:Positive peritoneal cytology (Cy+) is considered a form of microscopic dissemination and a poor prognostic factor in resected pancreatic cancer (PC). However, the clinical implications of equivocal categories such as atypia of undetermined significance (AUS) and suspicious for malignancy (SFM) remain unclear.METHODS:We retrospectively analyzed patients with PC who underwent surgery at 13 high-volume centers between January 2009 and December 2018. Inclusion criteria were: 1) cytology results of AUS, SFM, or malignant (MAL); 2) resectable (R) or borderline resectable (BR); 3) no other macroscopic metastases; and 4) no preoperative therapy.RESULTS:A total of 239 cases were included (AUS: 58, SFM: 31, MAL: 150), with R/BR = 196/43. Survival curves for SFM closely resembled those for MAL but differed from AUS. Grouped analysis showed that SFM + MAL patients had significantly shorter median overall survival (OS) than AUS patients (19.6 vs. 28.0 months, HR 1.61, P < 0.01) and shorter recurrence-free survival (RFS: 8.0 vs. 12.7 months, HR 1.53, P = 0.01). This trend persisted in resectable cases (OS: 21.1 vs. 30.5 months, HR 1.74; RFS: 9.1 vs. 14.2 months, HR 1.57; all P < 0.01).CONCLUSIONS:The cytology of SFM in PC is associated with a prognosis comparable to that of MAL, suggesting the need for cautious clinical interpretation and potential reclassification. |
| DOI | 10.1016/j.pan.2025.05.006 |
| PMID | 40442012 |